In this episode, Martin lays out his bearish thesis on AMD and explains why he believes expectations surrounding AI growth have pushed its valuation to unsustainable levels. He also discusses the outlook for Ozempic and the increasingly competitive GLP-1 drug market, analyzing Novo Nordisk’s pipeline, market position, valuation, and the risks he believes could challenge its future growth.
Podden och tillhörande omslagsbild på den här sidan tillhör
Urban Tapes. Innehållet i podden är skapat av Urban Tapes och inte av,
eller tillsammans med, Poddtoppen.
